Drug Trial Radar · NCT07874633
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
432
Planned (sponsor's estimate)
Start
Oct 28, 2026
Primary completion
Jun 6, 2028
Study completion Aug 15, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Overweight and obesity are long-term health conditions that can increase the possibility of serious health problems. These problems include heart disease, type 2 diabetes (a condition that causes high blood sugar), and other medical conditions. The purpose of this study is to learn whether berobenatide (PF-08653944) is safe and effective for adults in China who are overweight or obese. Researchers will compare berobenatide with a placebo. A placebo looks like study treatment but does not contain active medicine. About 432 adults will take part in this study. This study is seeking adults who * are obese * are overweight with certain weight-related health conditions. Some participants may also have type 2 diabetes. Specific eligibility requirements will be reviewed by the study doctor before enrollment. Participants will be randomly assigned to receive either berobenatide or placebo. Study treatment will be administered as a shot under the skin. All participants will also receive lifestyle counseling throughout the study. Researchers will monitor participants throughout the study. They will assess participants' body weight, overall health, and any reactions that may occur. During the study, participants will attend study visits and complete study-related assessments. Participants may take part in the study for up to approximately 59 weeks. This period includes screening, treatment, and follow-up visits. The information learned from this study may help researchers better understand whether berobenatide could be a treatment option for adults living with overweight or obesity.
Conditions
- Obesity
- Overweight
Interventions
BerobenatideDrug
By Subcutaneous Injection
PlaceboOther
By Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in body weightTime frame: Baseline, Week 48
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
The Second People's Hospital of Hefei
Hefei, Anhui, China · Not yet recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Huizhou Central People's Hospital
Huizhou, Guangdong, China · Not yet recruiting
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.